Prodromal Parkinson disease in patients with idiopathic hyposmia.

Idiopathic hyposmia Movement Disorders Society Research criteria for prodromal Parkinson disease Parkinson disease Prodromal Parkinson disease REM sleep behavior disorder

Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 17 05 2020
accepted: 02 07 2020
revised: 01 07 2020
pubmed: 18 7 2020
medline: 22 6 2021
entrez: 18 7 2020
Statut: ppublish

Résumé

Idiopathic hyposmia (IH) is a prodromal marker of Parkinson disease (PD). However, IH is common in the general population and only a minority will develop PD. Identification of individuals with IH at prodromal stage of PD would serve to select them to implement neuroprotective agents, when available. To identify prodromal PD in IH patients using the Movement Disorders Society (MDS) research criteria for prodromal PD. We applied the MDS research criteria for prodromal PD to 25 consecutive patients older than 50 years who were self-referred for smell loss and had IH, and to 18 controls. A number of risk and prodromal PD markers were assessed in all participants including REM sleep behavior disorder (RBD) by video-polysomnography and nigrostriatal dopaminergic dysfunction by DAT-SPECT. After follow-up of 4.7 ± 2.2 years, participants were re-assessed to look for incident PD. Prodromal PD probability was higher in patients than in controls (19.45 ± 34.9% versus 1.74 ± 4.48%; p = 0.019). Four (16%) patients met the criteria of prodromal PD surpassing 80% probability (99.8%, 99.5%, 88.3%, 86.4%). Three (12%) patients had RBD and four (16%) abnormal DAT-SPECT. At the end of follow-up, one (4%) IH patient who had RBD and baseline prodromal PD probability of 86.4% developed PD, while all controls remained disease free. Prodromal PD is infrequent among IH patients. MDS research criteria for prodromal PD are useful to identify a subgroup of IH patients at high risk of PD when RBD is assessed by video-polysomnography and nigrostriatal dopamine deficiency with DAT-SPECT.

Sections du résumé

BACKGROUND BACKGROUND
Idiopathic hyposmia (IH) is a prodromal marker of Parkinson disease (PD). However, IH is common in the general population and only a minority will develop PD. Identification of individuals with IH at prodromal stage of PD would serve to select them to implement neuroprotective agents, when available.
OBJECTIVE OBJECTIVE
To identify prodromal PD in IH patients using the Movement Disorders Society (MDS) research criteria for prodromal PD.
METHODS METHODS
We applied the MDS research criteria for prodromal PD to 25 consecutive patients older than 50 years who were self-referred for smell loss and had IH, and to 18 controls. A number of risk and prodromal PD markers were assessed in all participants including REM sleep behavior disorder (RBD) by video-polysomnography and nigrostriatal dopaminergic dysfunction by DAT-SPECT. After follow-up of 4.7 ± 2.2 years, participants were re-assessed to look for incident PD.
RESULTS RESULTS
Prodromal PD probability was higher in patients than in controls (19.45 ± 34.9% versus 1.74 ± 4.48%; p = 0.019). Four (16%) patients met the criteria of prodromal PD surpassing 80% probability (99.8%, 99.5%, 88.3%, 86.4%). Three (12%) patients had RBD and four (16%) abnormal DAT-SPECT. At the end of follow-up, one (4%) IH patient who had RBD and baseline prodromal PD probability of 86.4% developed PD, while all controls remained disease free.
CONCLUSIONS CONCLUSIONS
Prodromal PD is infrequent among IH patients. MDS research criteria for prodromal PD are useful to identify a subgroup of IH patients at high risk of PD when RBD is assessed by video-polysomnography and nigrostriatal dopamine deficiency with DAT-SPECT.

Identifiants

pubmed: 32676768
doi: 10.1007/s00415-020-10048-6
pii: 10.1007/s00415-020-10048-6
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3673-3682

Auteurs

Paula Marrero-González (P)

Center for Sleep Disorders, Neurology Service, Hospital Clinic de Barcelona, Universitat de Barcelona, IDIBAPS, CIBERNED: CB06/05/0018-ISCIII, Villarroel 170, 08036, Barcelona, Spain.

Alex Iranzo (A)

Center for Sleep Disorders, Neurology Service, Hospital Clinic de Barcelona, Universitat de Barcelona, IDIBAPS, CIBERNED: CB06/05/0018-ISCIII, Villarroel 170, 08036, Barcelona, Spain. airanzo@clinic.cat.

David Bedoya (D)

Rhinology Unit and Smell and Taste Clinic, Otorhinolaryngology Service, Hospital Clinic de Barcelona, Universitat de Barcelona, IDIBAPS, CIBERES, Barcelona, Catalonia, Spain.

Mònica Serradell (M)

Center for Sleep Disorders, Neurology Service, Hospital Clinic de Barcelona, Universitat de Barcelona, IDIBAPS, CIBERNED: CB06/05/0018-ISCIII, Villarroel 170, 08036, Barcelona, Spain.

Aida Niñerola-Baizán (A)

Nuclear Medicine Department, Hospital Clínic Barcelona and Biomedical Research Networking Center of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain.

Andrés Perissinotti (A)

Nuclear Medicine Department, Hospital Clínic Barcelona and Biomedical Research Networking Center of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain.

Carles Gaig (C)

Center for Sleep Disorders, Neurology Service, Hospital Clinic de Barcelona, Universitat de Barcelona, IDIBAPS, CIBERNED: CB06/05/0018-ISCIII, Villarroel 170, 08036, Barcelona, Spain.

Isabel Vilaseca (I)

Otorhinolaryngology Service, Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, CIBER Enfermedades Respiratorias, Bunyola, Barcelona, Spain.

Isam Alobid (I)

Rhinology Unit and Smell and Taste Clinic, Otorhinolaryngology Service, Hospital Clinic de Barcelona, Universitat de Barcelona, IDIBAPS, CIBERES, Barcelona, Catalonia, Spain.
Otorhinolaryngology Service, Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, CIBER Enfermedades Respiratorias, Bunyola, Barcelona, Spain.

Joan Santamaría (J)

Center for Sleep Disorders, Neurology Service, Hospital Clinic de Barcelona, Universitat de Barcelona, IDIBAPS, CIBERNED: CB06/05/0018-ISCIII, Villarroel 170, 08036, Barcelona, Spain.

Joaquim Mullol (J)

Rhinology Unit and Smell and Taste Clinic, Otorhinolaryngology Service, Hospital Clinic de Barcelona, Universitat de Barcelona, IDIBAPS, CIBERES, Barcelona, Catalonia, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH